EP-1228 : UK NCRI CTRad consensus on drug and radiotherapy combination platform studies in NSCLC by Hanna, G. et al.
This is a repository copy of EP-1228 : UK NCRI CTRad consensus on drug and 
radiotherapy combination platform studies in NSCLC.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/158539/
Version: Published Version
Proceedings Paper:
Hanna, G., McDonald, F., Greystoke, A. et al. (7 more authors) (2017) EP-1228 : UK NCRI
CTRad consensus on drug and radiotherapy combination platform studies in NSCLC. In: 
Radiotherapy and Oncology. ESTRO 36 - European Society for Radiotherapy & Oncology, 
05-09 May 2017, Vienna, Austria. Elsevier , S662-S663. 
https://doi.org/10.1016/s0167-8140(17)31663-8
Article available under the terms of the CC-BY-NC-ND licence 
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
S662                                                                                     ESTRO 36 
 _______________________________________________________________________________________________ 
 
 
total BED10Gy (a/b = 10) prescribed dose as treatment 
related factors were analysed using log-rank test to 
determine their impact on outcome. 
Results  
Between 05/2010 and 03/2016, 131 patients with 164 
lesions were irradiated. Treatments were delivered 
3x/week in a median of three fractions. According to the 
RECIST criteria a complete or partial response were 
observed in 86 and 27 lesions, while 12 remained stable. 
After mean follow-up of 14 months, the 1 and 2-year 
LC/lung PFS/DPFS/OS were 85.0/62.2/82.6/91.3% and 
69.0/44.8/69.8% and 77.9% respectively. Age (>65 years) 
and controlled primary tumour influenced DPFS (p=0.017) 
and OS (p=0.02) respectively, while LC and OS differed 
significantly for BED10Gy (>120 vs. <=120 Gy, p<0.001 and 
p =0.016) and primary histology (adenocarcinoma or 
others, p=0.003 and p=0.006) (Figure 1 and 2). Grade 
1/2/3/4 fatigue, chest pain and dyspnoea were present in 
77/3/0/0, 20/0/0/0 and 26/1/1/0 treatments as acute, 
while 22/0/0/0, 14/37/0/0 and 18/2/3/1 as late toxicity. 
One patient died due to RT-induced pulmonary 
haemorrhage. 
 
Figure 1: Kaplan-Meier curves and log-rank test for LC 
 
 
Figure 2: Kaplan-Meier curves and log-rank test for OS 
 
Conclusion  
Our favourable outcome data reinforces the paradigm 
shift of SBRT in oligometastatic pulmonary disease. Longer 
follow-up is required especially concerning patient 
selection and fractionation schedules to secure adequate 
dose and to further strengthen the position of this 
treatment  option. 
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Purpose or Objective   
To identify the predictive factors for pr ogression of 
radiological radiation pneumonitis (RP) to symp tomatic 
RP and to evaluate the usefulness of the neutrophil-
lymphocyte ratio (NLR) as a severity and prognosis marker 
of RP in stage III non-small-cell lung cancer (NSCLC) 
patients treated with definitive concurrent 
chemoradiotherapy (CCRT). 
Material and Methods   
The study included 61 patients treated between January 
2010 and December 2015. The patient char acteristics, 
tumor factors, laboratory findings, and treatment 
parameters were recorded. Among patients with 
radiological RP, the predictive factors associated with 
progression to symptomatic RP were assessed. 
Results  
Of the 61 patients, 47 (77%) showed radiological RP at a 
median of 78 days after radiation therapy (RT) 
completion, and of these, 15 patients (32%) developed 
symptomatic RP. The interval between RT completion and 
radiological RP was shorter in patients with progression 
than in those without progression (p=0.001), and in the 
latent period within 2 months, progression was highly 
probable (p=0.002). Stage and the RT technique were 
related to symptomatic RP (p=0.046 and p=0.046, 
respectively). Among dosimetric factors, lung volume 
receiving ≥20 Gy (V20) of >30% was the most significant 
factor for symptomatic RP (p=0.001). The NLR (NLRR) and 
C-reactive protein level at radiological RP were higher in 
patients with symptomatic RP than in other patients 
(p=0.012 and p=0.067, respectively). In multivariate 
analysis, V20>30% and NLRR>6 were associated with 
symptomatic RP development. In receiver operating 
characteristic curve analysis, the combination of NLRR>6 
and V20>30% improved the predictive power for 
symptomatic RP. 
Conclusion  
The NLR at radiological RP is a useful biomarker for 
predicting symptomatic RP development after CCRT in 
stage III NSCLC patients. Patients showing early 
appearance of radiological RP along with the combination 
of a high NLR and V20>30% should be managed with caution 
as there is a high risk of symptomatic RP. 
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Purpose or Objective  
Local control and systemic control need to be improved 
for patients with locally advanced and metastatic non-
small cell lung cancer (NSCLC) and novel mechanism based 
therapies (MBT) drug and radiotherapy (RT) combinations 
have the potential to achieve this.  Current models of 
early phase clinical trials for these combinations are 
developed in a piecemeal fashion leading to inefficiency 
and slow progress. We describe a joint UK National Cancer 
Research Institute Clinical and Translational Radiotherapy 
Research Working Group (NCRI CTRad) and Lung Clinical 
Studies Group (NCRI Lung CSG) initiative to develop two 
platform studies of MBT/RT combinations in the treatment 
of NSCLC. 
Material and Methods  
NCRI CTRad and the NCRI Lung CSG held a two-day 
consensus meeting in Glasgow in February 2016 to 
consider the optimal approach in the development of 
MBT/RT combinations. Invited participants included UK 
clinical and medical oncologists, statisticians, 
methodologists and industry partners active in NSCLC 
research. The consensus achieved is presented. 
Results  
It was agreed to establish 2 platform studies which will run 
in parallel. In patients with locally advanced NSCLC, a 
phase 1 study will test novel MBT agents, such as DNA 
damage repair inhibitors, in combination with curative 
intent RT in patients with stage 3 NSCLC. We agreed to 
use conventional fractionation to a dose of 60-66 Gray in 
30-33 fractions. In patients with metastatic disease, a 
phase 2 study will investigate RT in combination with 
immunomodulating agents. It will investigate the use of 
RT under two scenarios: 1) palliative radiotherapy 
delivered for the purpose of symptomatic control; 2) 
radiotherapy delivered for the purpose of immune 
stimulation. Both platform studies will involve significant 
pre-clinical and translational components, will have 
Patient/Consumer involvement at the core of study 
development and seek to follow the recent NCRI CTRad 
Academia-Pharma Joint Working Group consensus for the 
clinical development of new drug-radiotherapy 
combinations. 
Conclusion  
The UK consortium establishing two platform studies of 
novel MBT/RT combinations offers a unique opportunity to 
rapidly improve outcomes for patients with NSCLC in a 
collaborative fashion. 
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Purpose or Objective  
The survival of patients with LA-NSCLC treated with 
concurrent chemo-radiation (CRT) remains poor. We have 
performed a phase II study using the tyrosine kinase 
inhibitor, erlotinib, as radiosensitizer. Due to slow 
accrual, the study was terminated prematurely. We here 
report survival and toxicity data from the study. 
Material and Methods  
The main inclusion criteria were histological or cytological 
proven stage IIB-IIIAB NSCLC, PS 0-2. The patients were 
not candidate for CRT. The prescribed dose was 66 
Gy/33F, 5F/week. The radiation technique was IMRT or 
ARC-therapy. No elective lymph nodes were treated. 
During RT, oral erlotinib was administered 150 mg daily. 
No chemotherapy was applied concurrent with RT. 
The endpoints included overall survival (OS). The results 
were compared with the survival data from 48 patients 
treated for LA-NSCLC within the same period and in the 
same centers in a phase II study using oral vinorelbine 
(Vino) as radiosensitizer together with radiation 66 
Gy/33F.  However, the inclusion criteria for this study 
excluded patients in PS 2, and FEV1<1.  
Pt. 
characteristi
cs 
 
Presen
t study 
N=15 
Vino-
study 
N=48 
P-
valu
e 
 
Age Median (range) 
75.3 
(49.1; 
85.0) 
64.8 
(44.4; 
79.4) 
0.00
0 
 
Gender Male/Female 9/6 27/21 ns  
Performance 
status 
0/1/2 3/8/1 28/20 
0.00
0 
 
Histology 
Squam/Adeno/N
OS 
8/6/1 
17/32/1
0 
ns  
Stage 2B/3A/3B 2/10/3 3/35/10 ns  
Results  
From July 2009-August 2013, 15 patients from 3 centers 
entered the study. 
 
The median OS was 16.9 months; the 1- and 2-year survival 
was 53% and 40%. In comparison, the survival data from 
the vino-trial was 21.0 months, 79% and 46% (P=0.11), see 
Fig 1. However, the patients in the vino-study were 
younger, and had better PS, see Table 1.   
In the erlotinib study, 3 patients (20%) developed 
pneumonitis grade 3. In the vino-study, 8 patients (17%) 
developed grade 3 pneumonitis (p=ns). 
Conclusion  
This phase II study was prematurely closed. A trend for 
inferior survival was observed using erlotinib compared to 
vinorelbine as radiosensitizer, but the small number of 
patients and differences between the populations treated 
made the result inconclusive. However, the regimen 
erlotinib-RT was well tolerate 
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